Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Chengdu Kanghong's KH815 enters human testing this month.
